2019 Annual Meeting of the American Association for the Study of Liver Diseases*

Download All
November 8-12, 2019; Boston, Massachusetts
Download slides or audio and review Capsule Summaries on practice-changing viral hepatitis and NAFLD/NASH data from Boston.


Capsule Summary Slidesets

Nonrandomized, prospective study showed that a formal in-person education session resulted in sustained improvement in patients’ HBV knowledge, which was associated with downstream improvements in HBV monitoring and management.

Released: November 16, 2019

This large population-based observational study demonstrated that medical follow-up every 3-6 months associated with significantly lower HCC mortality in patients with CHB.

Released: November 19, 2019

Large study from Hong Kong finds that the risk of developing HCC is equally low for patients with spontaneous HBsAg loss and NA-induced HBsAg clearance.

Released: November 19, 2019

HCV is a common cause of HCC among African-born immigrants in Minnesota.

Released: November 16, 2019

Patients on stable nucleos(t)ide analogue therapy who added or switched to pegIFN had significantly better HBeAg loss rates and HBsAg level reductions compared with patients who continued nucleos(t)ide analogue therapy alone.

Released: November 16, 2019

External validation supports scoring system for identifying patients with low risk of HCC following SVR.

Released: November 18, 2019

HCV reinfection rates in British Columbia were relatively low following SVR with DAA treatment but were higher among persons who inject drugs vs the overall cohort.

Released: November 20, 2019

Presence of advanced hepatic fibrosis, CKD, and elevated cardiac risk score increase risk of mortality in all patients with NAFLD, regardless of BMI.

Released: November 16, 2019

Obeticholic acid 10 mg and 25 mg improved liver fibrosis, steatohepatitis, and liver biochemistry in expanded ITT population that included patients with fibrosis stages 1-3.

Released: November 12, 2019

This small study showed that a short preemptive course of GLE/PIB + EZE given pre- and post-transplant prevented HCV transmission in all HCV-uninfected patients who received organs from HCV-infected donors.

Released: November 16, 2019
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings